Skip to main content
Fig. 7 | Cancer Cell International

Fig. 7

From: ZBTB7A, a potential biomarker for prognosis and immune infiltrates, inhibits progression of endometrial cancer based on bioinformatics analysis and experiments

Fig. 7

ZBTB7A can repress E2F4 transcription in endometrial cancer cells. a E2F4 mRNA levels with ZBTB7A overexpression in Ishikawa cells. b E2F4 promoter transcriptional activity was detected by Luciferase assay when cells were transfected with 300 ng ZBTB7A plasmid. c Schematic diagram of ZBTB7A binding motif from JASPAR Database. d Three prospected ZBTB7A responsive elements (E1, E2, and E3) in the E2F4 promoter part. TSS represents the transcriptional start site of E2F4. e Three potential ZBTB7A binding sites of the E2F4 promoter was eliminated respectively and named Del-E1, Del-E2, and Del-E3. The transcriptional activity of three depleted promoter were examined by Luciferase assay when ZBTB7A plasimid was transfected into Ishikawa cells. f Chromatin immunoprecipitation (ChIP) assay revealed that ZBTB7A might bind to the E1 part of E2F4 promoter in Ishikawa. The values are presented as the means ± SD from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page